Anterogen will be completing data cleaning on its Phase III trial (DFU-301) that was conducted in Korea at the end of August at the earliest. If the analysis goes as planned, the company plans to seek marketing authorization for its product after completing the analysis.

Anterogen announced these plans at the IR meeting on the 28th. According to IR, Anterogen is currently developing a dressing-type stem cell therapy product for the treatment of diabetic foot ulcers.

Two Phase III trials - DFU-301and DFU-302 – had been ongoing for the said product in Korea. Regarding the DFU-301 trial that is now complete, a company official said, “The company aims to complete data cleani